Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Replimune Group Inc. (REPL) and Encourages Stockholders to Learn More About the Investigation

NEW YORK CITY, NY / ACCESS Newswire / July 31, 2026 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Replimune Group Inc. ("Replimune" or "the Company") (NASDAQ:REPL). Investors who purchased Replimune securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/REPL.

Replimune Investigation Details

On July 28, 2026, the US Food and Drug Administration ("FDA") released briefing documents related to Replimune's lead trial for its drug vusolimogene oderparepvec, or RP1, for skin cancer. The briefing documents state the FDA has deemed the single-arm mid-stage study submitted by Replimune to support the approval of the drug as "not interpretable." The assessment used in the study "confounds interpretation of the reported efficacy results and limits FDA's ability to verify the reported results," the FDA reviewers said. Following this news, Replimune's stock price drropped $3.27, or 37.89% in intraday trading on July 28, 2026.

What's Next for Replimune Investors?

If you are aware of any facts relating to this investigation or purchased Replimune securities, you can assist this investigation by visiting the firm's site: bgandg.com/REPL. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 917-590-0911

No Cost to Replimune Investors

We, Bronstein, Gewirtz & Grossman, LLC, represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman, LLC for Replimune Securities Investigation?

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

"Our practice centers on restoring investor capital and ensuring corporate accountability, which serves to uphold the essential integrity of the marketplace," said Peretz Bronstein, Founding Partner of Bronstein, Gewirtz & Grossman, LLC.

Contact Info

Peretz Bronstein, Esq. or Nathan Miller

Bronstein, Gewirtz & Grossman, LLC

917-590-0911 | [email protected]

Attorney advertising.

Prior results do not guarantee similar outcomes.

SOURCE: Bronstein, Gewirtz & Grossman, LLC